anti-Crry antibody product blog
Tags: Antibody; Monoclonal Antibody; Crry; anti-Crry antibody;
The Crry n/a (Catalog #MBS584442) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Crry, Rat, mAb TLD-1C11 reacts with Rat and may cross-react with other species as described in the data sheet. MyBioSource\'s Crry can be used in a range of immunoassay formats including, but not limited to, F, Flow Cytometry (FC/FACS), FS, Immunofluorescence (IF), Western Blot (WB).. Researchers should empirically determine the suitability of the Crry n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Product Description: The monoclonal antibody TLD-1C11 reacts with rat-complement regulator Crry. Complement comprises a system of soluble serum proteins that, upon activiation by antibody (classical pathway), sugars (lectin pathway), or bacterial and foreign surfaces (alternative pathway), directly causes cell damage. Complement is constantly activated at low levels in serum, requiring cells to be protect themselves from damage. In human, cells are protected from complement-mediated damage by expression of membrane-bound complement regulatory proteins, which act at serveral points along the cascade. Human cells are protected by decay-accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and membrane attack complex inhibitor protein 1 (MIN1, CD59). Furthermore the rat analogues of DAF, MCP and CD59 have been characterized. Rats and mice express an unique membrane complement regulator of the activating pathways, called complement receptor type-1 related gene Y (Crry). In rats there are two isoforms of Crry, with six or seven short consensus repeats (SCR), encoding 65-70 and 75-85 kDa proteins, respectively, which are both transmembrane anchored. Although Crry has the functional properties of both DAF and MCP, it does not replace them. All rat blood cells express Crry whereas approximately 37 and 39% of the rat T cells express respectively DAF and CD59. Studies in rat revealed that despite lacking DAF and CD59, these double-negative rat T cells were not more susceptible to homologous complement lysis than cells that expressed both DAF and CD59. However, blocking of the only other known rat complement regulator, Crry, enhanced lysis only at the double-negative cells. In rats, Crry exerts powerful control in the activation pathways where it acts both as a cofactor and as a decay accelerator to inactivate convertases. Crry has been succesfully expressed and refolded in bacteria. The refolded protein has full-complement regulatory activity in vitro, and has been applied in rat models of arthritis and other inflammatory diseases. The monoclonal antibody TLD-1C11 can be used to block autoimmune phenomena in rats.
Immunogen: rat microglial cells. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Crry are readily searchable from our website. Different antibodies against the same target such as Crry may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.